Alnylam Pharmaceuticals has seen a notable surge in its stock price, bolstered by the promising results and success of its transformative
RNAi therapeutics. The company's victories are marked by its drug for
ATTR-CM showing promise, obtaining regulatory filing for
cardiomyopathy drug in the EU, positive results in a key study for reducing risk of death and heart issues, and a 234% gain for investors who held the stock for five years. A new drug for rare heart disease -
Vutrisiran, has cleared a path for regulatory approval following successful trial results. However, there are challenges, including a legal hurdle with Moderna over COVID-19 shots patent and the sale of $5.0m of shares, suggesting hesitancy among the insiders. Mixed feelings were exhibited regarding heart disease drug data, causing shares to slide then surge again. The company's CEO expressed readiness for competition and optimism for profitability, reinforcing Alnylam's momentum in the bio-tech market.
Alnylam Pharmaceuticals News Analytics from Thu, 15 Feb 2024 08:00:00 GMT to Sat, 26 Oct 2024 09:35:56 GMT -
Rating 9
- Innovation 8
- Information 8
- Rumor 4
